Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Children

This ongoing Phase 3 trial is a multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the safety and immunogenicity of the CHIKV VLP vaccine in children aged 1 to <12 years. The study aims to enroll 720 participants and is sponsored by Bavarian Nordic. The primary immunogenicity endpoint is the seroresponse rate on Day 22 in seronegative children, while safety endpoints include the incidence of adverse events of special interest (AESI), medically attended adverse events (MAAEs), and serious adverse events (SAEs). Additionally, the study monitors unsolicited adverse events through Day 29. The trial's primary completion is anticipated by December 2028. The results will provide critical insights into the vaccine's potential to protect children against the chikungunya virus, with safety and immunogenicity being key measures of success.

This study focuses on chikungunya virus, which can cause fever and joint pain. Researchers are testing a new vaccine called CHIKV VLP in children aged 1 to under 12 years. They will check if the vaccine is safe and if it helps children develop protection against the virus. The study will involve about 720 children, and they will receive either the vaccine or a placebo, which looks like the vaccine but has no active ingredients. The researchers will monitor the children for any side effects and measure how well the vaccine works. If successful, this vaccine could provide a way to protect children from chikungunya, which currently has no specific treatment. However, it’s important to note that the study is still in progress, and results will take time to analyze. Parents should stay informed and consult with their healthcare providers about vaccination options.